Depression is a growing mental health concern, especially among young adults. New AI-powered research offers a rapid, objective screening tool to identify those at high risk using eye tracking technology. This innovative approach could revolutionize early detection and intervention. Key Facts: Depression is the leading cause of disability worldwide, often starting in young adulthood. Early …
Alzheimer’s disease (AD) is a growing global health concern, but current drug therapies have shown limited effectiveness for symptom management and disease modification. Medium chain triglycerides (MCTs) have emerged as a potential nutritional therapy, but evidence remains inconclusive. Key Facts: MCTs may provide an alternative brain fuel source and reduce AD biomarkers like amyloid-beta. Small …
Headaches are an extremely prevalent health issue, but medications can have side effects or lose effectiveness over time. Primary headaches, which have no identified underlying cause, include migraine, tension-type headache, and cluster headache. These cause significant disability worldwide. While medications are commonly used, non-pharmacological treatments are gaining interest as alternatives or additions to drug regimens. …
Transcranial alternating current stimulation (TACS) is an emerging non-invasive brain stimulation technique that shows promise for enhancing cognition and treating psychiatric conditions like depression and schizophrenia. Recent research indicates TACS may improve symptoms and function by modulating brain oscillations and connectivity. Key facts: TACS delivers alternating electrical current to the brain at specific frequencies, which …
Personality disorders like borderline and avoidant involve differences in brain structure and function that relate to symptoms. New research sheds light on the neurobiology underlying these disorders. Key Facts: Borderline patients showed reduced medial prefrontal cortex (MPFC) volume compared to healthy controls. MPFC is involved in cognitive control of emotion. Both borderline and avoidant patients …
Depression affects over 300 million people globally. Current treatments have limited efficacy for many patients. Exciting new research highlights the potential of allopregnanolone agonists like brexanolone and zuranolone as more targeted, rapid-acting antidepressants. Key Facts: Allopregnanolone is a neurosteroid that regulates mood and is decreased in depression. Its agonists boost allopregnanolone activity. Brexanolone is the …
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders affecting children. A new randomized controlled trial published in the Journal of Korean Medical Science suggests that mobile neurofeedback training may help improve attention and reduce symptoms in children with ADHD. Key Takeaways: 74 children aged 8-15 with ADHD participated in a …
Major depressive disorder affects over 17 million American adults each year. For up to 30% of these patients, standard antidepressant medications fail to provide adequate symptom relief – a condition known as treatment-resistant depression (TRD). Now, new research suggests amphetamine-based stimulants like Adderall may be an effective augmentation strategy for TRD when other therapies have …
Vagus nerve stimulation (VNS) is an emerging form of brain stimulation showing promise for treating depression. Though still considered experimental, VNS has a long history dating back over 100 years. Recent advances are unlocking its potential as a new tool for mood disorders. Key Facts: VNS stimulates the vagus nerve, which connects to emotion regulation …
Suicide is a major public health problem, with over 700,000 people dying by suicide every year globally. Identifying factors that may indicate risk for suicidal thoughts and behaviors is an important area of research, as this could aid prevention and intervention efforts. Some studies have investigated whether asymmetric brain activity, as measured by electroencephalography (EEG), …
